Use of selective antagonists and antisense oligonucleotides to evaluate the mechanisms of BUBU antinociception

European Journal of Pharmacology

Volumn 383, Issue 1, 1999, Pages 29-37

  Hutcheson, Daniel M ^a   Sánchez Blazquez, Pilar ^b   Rodriguez Diaz, Marta ^b   Garzon, Javier ^b   Schmidhammer, Helmut ^c   Borsodi, Anna ^d,e   Roques, Bernard P ^a   Maldonado, Rafael ^a,f  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b CSIC   (Spain)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d INSTITUTE OF BIOCHEMISTRY   (Hungary)

^e UNIVERSITY OF SZEGED   (Hungary)

^f UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Opioid receptor; Antinociception; Antisense oligonucleotide; BUBU; Cyprodime; Naltrindole

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CYPRODIME; DELTA OPIATE RECEPTOR; LEUCINE ENKEPHALIN[2 DEXTRO O TERT BUTYLSERINE 6 O TERT BUTYLTHREONINE]; MU OPIATE RECEPTOR; NALTRINDOLE; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; HOT PLATE TEST; IMMERSION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS; ANIMALS; MALE; MICE; MORPHINANS; NALTREXONE; NARCOTIC ANTAGONISTS; OLIGONUCLEOTIDES, ANTISENSE; OLIGOPEPTIDES; PAIN MEASUREMENT; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

EID: 0033592704     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00611-1     Document Type: Article

References (65)

1. Baamonde A., Daugé V., Gacel G., Roques B.P. Systemic administration of (Tyr-D-Ser-(O-tert-butyl)-Gly-Phe-Leu-Thr-(O-tert-butyl), a highly selective δ-opioid agonist, induces μ-receptor-mediated analgesia in mice. J. Pharmacol. Exp. Ther. 257:1991;767-773.
2. Baamonde A., Daugé V., Ruiz-Gayo M., Fulga I.G., Turcaud S., Fournié-Zaluski M.C., Roques B.P. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur. J. Pharmacol. 216:1992;157-166.
3. Basbaum A.I., Fields H.L. Endogenous opioid pain control systems: brainstem spinal pathways and endorphin circuitry. Annu. Rev. Neurosci. 7:1984;309-338.
4. Besson J.M., Chaouch A. Peripheral and spinal mechanisms of nociception. Physiol. Rev. 67:1987;67-186.
5. 4]deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid δ-receptor. Life Sci. 55:1994;PL37-PL43.
6. Bilsky E.J., Bernstein R.N., Hruby V.J., Rothman R.B., Lai J., Porreca F. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptors in vivo. J. Pharmacol. Exp. Ther. 277:1996;491-501.
7. Cáceres A., Kosik K.S. Inhibition of neurite polarity by tau antisense oligodeoxynucleotides in primary cerebellar neurons. Nature. 343:1990;461-463.
8. Chaillet P., Coulaud A., Zajac J.-M., Fournié-Zaluski M.C., Costentin J., Roques B.P. The μ- rather than the δ-subtype of opioid receptors appears to be involoved in enkephalin-induced analgesia. Eur. J. Pharmacol. 101:1984;83-90.
9. Chen X.-H., Adams J.U., Geller E.B., Deriel J.K., Adler M.W., Liu-Chen L.-Y. An antisense oligodeoxynucleotide to mu-opioid receptors inhibits mu-opioid receptor agonist-induced analgesia in rats. Eur. J. Pharmacol. 275:1995;105-108.
10. Chiasson B.J., Armstrong J.N., Hooper M.L., Murphy P.R., Roberston H.A. The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell. Mol. Neurobiol. 14:1994;507-521.
11. Chien C.C., Brown G., Pan Y.X., Pasternak G.W. Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa opioid receptor. Eur. J. Pharmacol. 253:1994;R7-R8.
12. 5). Neuropeptides. 5:1985;311-314.
13. Cowan A., Zhu X.Z., Mosberg H.I., Omnaas J.R., Porreca F. Direct dependence studies in rats with agents selective for different types of opioid receptor. J. Pharmacol. Exp. Ther. 246:1988;950-955.
14. 6(O-tert-butyl): two new enkephalin analogs with both a good selectivity and a high affinity toward δ-opioid binding sites. J. Biol. Chem. 263:1988;4124-4129.
15. Delay-Goyet P., Ruiz-Gayo M., Baamonde A., Gacel G., Morgat J.-L., Roques B.P. Brain passage of BUBU, a highly selective and potent agonist for delta opioid receptors: in vivo binding and mu versus delta receptors occupancy. Pharmacol. Biochem. Behav. 38:1991;155-162.
16. Dickenson A.H. Mechanisms of the analgesic actions of opiates and opioids. Br. Med. Bull. 47:1991;690-702.
17. Dickenson A.H., Sullivan A., Roques B.P. Evidence that the endogenous enkephalins and the delta opioid receptor agonists have a common site of action in spinal antinociception. Eur. J. Pharmacol. 148:1988;437-439.
18. Eddy N.B., Leimbach D. Synthetic analgesics (II): dithienylbutenyl- and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107:1953;385-389.
19. Evans C.J., Keith D.E., Morrison H., Magendzo K., Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science. 258:1992;1952-1955.
20. Gacel G., Daugé V., Breuzé P., Delay-Goyet P., Roques B.P. Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for delta opioid receptors. J. Med. Chem. 31:1988;1891-1897.
21. Haley T.J., McCormick W.G. Pharmacological effects produced by intra-cerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
22. Heyman J.S., Mulvaney S.A., Mosberg H.I., Porreca F. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice. Brain Res. 420:1987;100-108.
23. 2 and γ-aminobutyric acid B receptors in rat cerebellar granule cells. J. Pharmacol. Exp. Ther. 264:1993;423-430.
24. Hruby V.J., Misicka A., Lipkowski A.W., Haaseth R., Bartosz H., Qian X., Collins N., Meyer J.P., Szabo L., Polt R., Porreca F., Davis T., Yamamura H.I. New opioid compounds in analgesia. Regul. Pept. Suppl. I:1994;71-72.
25. Jackson H.C., Ripley T.L., Nutt D.J. Exploring δ-receptor function using the selective opioid antagonist naltrindole. Neuropharmacology. 28:1989;1427-1430.
26. Janssen P., Neimegeers C., Dony J. The inhibitory effects of fentanyl (R4263) and other morphine like analgesics, on the warm water induced tail reflex in rats. Arzneimittel-Forsch. 13:1963;502-507.
27. Jensen T.S., Yaksh T.L. Comparison of the antinocicepive action of mu and delta opioid receptor ligands in the periaqueductal grey matter, medial and paramedial ventral medulla in the rat as studied by micro-injection technique. Brain Res. 372:1986;301-312.
28. Kalso E.A., Sullivan A.F., McQuay H.J., Dickenson A.M. Spinal antinociception by Tyr-D-Ser(otbu)-Gly-Phe-Leu-Thr, a selective δ-opioid receptor agonist. Eur. J. Pharmacol. 216:1992;97-101.
29. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89:1992;12048-12052.
30. Kriel G., Barra D., Simmaco M., Erspamer V., Erspamer G.F., Negri L., Severni C., Corsi R., Melchiorri P. Deltorphin, a novel amphibian skin peptide with high selectivity and affinity for δ-opioid receptors. Eur. J. Pharmacol. 162:1989;123-128.
31. 2-agonist antinociception. NeuroReport. 5:1994;1049-1052.
32. Lee S.H., Kayser V., Guilbaud G. Antinociceptive effect of systemic kelatorphan, in mononeuropathic rats, involves different opioid receptor types. Eur. J. Pharmacol. 264:1994;61-67.
33. Ling G.S.F., Pasternak G.W. Spinal and supraspinal opioid analgesia in the mouse: the role of subpopulations of opioid binding sites. Brain Res. 271:1983;152-156.
34. Maldonado R., Feger J., Fournié-Zaluski M.C., Roques B.P. Differences in physical dependence induced by selective mu and delta opioid agonists and by endogenous enkephalins protected by peptidase inhibitors. Brain Res. 520:1990;247-254.
35. Mansour A., Watson S.J. Anatomical distribution of opioid receptors in mammalians: an overview. Herz A., Akil H., Simon E. Handbook of Experimental Pharmacology: Opioids I. 104/I:1993;79-105 Springer-Verlag, Berlin.
36. Matteucci M.D., Caruthers M.H. Synthesis of deoxyoligo nucleotides on a polymer support. J. Am. Chem. Soc. 103:1981;3185-3191.
37. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 383:1996;819-823.
38. Min B.H., Augustin L.B., Felsheim R.F., Fuchs J.A., Loh H.H. Genomic structure and analysis of promoter sequence of a mouse μ-opioid receptor gene. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9081-9085.
39. Mosberg H.I., Hurst R., Hruby V.J., Gee K., Yamamura H.I., Galligan J.J., Burks T.F. Bis-penicillamine enkephalins possess highly improved specificity toward δ-opioid receptors. Proc. Natl. Acad. Sci. U.S.A. 80:1983;5871-5874.
40. Negri L., Noviello L., Noviello V. Antinociceptive and behavioral effects of synthetic deltorphin analogs. Eur. J. Pharmacol. 296:1996;9-16.
41. Noble F., Roques B.P. Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphine. Neurosci. Lett. 185:1995;75-78.
42. Porreca F., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F. Role of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrintestinal transit effects and hot-plate analgesia in the mouse. J. Pharmacol. Exp. Ther. 230:1984;341-348.
43. 5)enkephalin in the mouse. J. Pharmacol. Exp. Ther. 241:1987;393-400.
44. Portoghese P.S., Sultana M., Takemori A.E. Naltrindole, a highly selective and potent non-peptide δ-opioid receptor antagonist. Eur. J. Pharmacol. 146:1988;185-186.
45. Reisine T. Opiate receptor. Neuropharmacology. 34:1995;463-472.
46. Rossi G.C., Leventhal L., Pan Y.-X., Cole J., Su W., Bodnar R.J., Pasternak G.W. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6β-glucuronide antinociception. J. Pharmacol. Exp. Ther. 281:1997;109-114.
47. Rossi G.C., Su W., Leventhal L., Su H., Pasternak G.W. Antisense mapping DOR-1 in mice: further support for δ receptor subtypes. Brain Res. 753:1997;176-179.
48. Sánchez-Blazquez P., Garzón J. Evaluation of delta receptor mediation of supraspinal opioid analgesia by in vivo protection against the β-FNA antagonist effect. Eur. J. Pharmacol. 159:1989;9-23.
49. Sánchez-Blazquez P., García-España A., Garzón J. In vivo injection of oligodeoxynucleotides to Ga subunits and supraspinal analgesia evoked by μ- and δ-opioid agonists. J. Pharmacol. Exp. Ther. 275:1995;1590-1596.
50. 2-opioid receptor. J. Pharmacol. Exp. Ther. 280:1997;1423-1431.
51. Schmidhammer H., Burkard W.P., Eggstein-Aeppli L., Smith C.F.C. Synthesis and biological evaluation of 14-alkoxymorphinans-2,1(-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist. J. Med. Chem. 32:1989;418-421.
52. Schmidhammer H., Smith C.F., Erlach D., Koch M., Krassnig R., Schwetz W., Wechner C. Cyprodime analogues: synthesis and pharmacological evaluation. Prog. Clin. Biol. Res. 328:1990;37-40.
53. Schmidhammer H., Smith C.F., Erlach D., Koch M., Krassnig R., Schwetz W., Wechner C. Synthesis and biological evaluation of 14-alkoxymorphinans: 3. Extensive study on cyprodime-related compounds. J. Med. Chem. 33:1990;1200-1206.
54. Shah S., Davis T., Yoburn B.C. The effect of naltrindole on spinal and supraspinal delta opioid receptors and analgesia. Life Sci. 55:1994;1451-1458.
55. Shook J.E., Pelton J.E., Lemcke P.K., Porreca F., Hruby V.J., Burks T.F. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions. J. Pharmacol. Exp. Ther. 242:1987;31-37.
56. Smadja C., Maldonado R., Turcaud S., Fournié-Zaluski M.C., Roques B.P. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology. 120:1995;400-408.
57. Sofuoglu M., Portoghese P.S., Takemori A.E. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257:1991;676-680.
58. Standifer K.M., Chien Ch.-Ch., Wahlestedt C., Brown G.P., Pasternak G.W. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron. 12:1994;805-810.
59. Sullivan A.F., Dickenson A.H., Roques B.P. Delta-opioid mediated inhibitors of acute and prolonged noxious-evoked responses in rat dorsal horn neurones. Br. J. Pharmacol. 98:1989;1039-1049.
60. Tseng L.F., Collins K.A., Kampine J.P. Antisense oligodeoxynucleotide to a δ-opioid receptor selectively blocks the spinal antinociception induced by δ-, but not μ- or κ-opioid receptor agonists in the mouse. Eur. J. Pharmacol. 258:1994;R1-R3.
61. Vu A., Hirschbein B.L. Internucleotide phosphite sulfurization with tetraethylthiuram disulfide phosphorothioate oligonucleotide synthesis via phosphoramidite chemistry. Tetrahedron Lett. 32:1991;3005-3008.
62. Wagner R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 372:1994;333-335.
63. Wahlestedt C., Pich E.M., Koob G.F., Yee F., Helling M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
64. Ward S.J., Takemori A.E. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. J. Pharmacol. Exp. Ther. 224:1983;525-530.
65. Zhang M., Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci. Lett. 161:1993;223-226.